NCT06515184PHASE3Recruiting
Coenzyme Q10 for Gulf War Illness: A Replication Study
University of California, San Diego
Start Date
9/13/2024
Completion Date
12/1/2027
Summary
The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
Eligibility Criteria
Age Range: 50 years to No maximum
Inclusion Criteria:
* Meets both CDC and Kansas deployment and symptom inclusion criteria.
* Does not have a disqualifying condition.
* Able to travel to a local Quest facility for study blood draws.
* Adequate internet access to allow ZoomPro visit participation and remote survey completion.
* Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms).
* Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.
Exclusion Criteria:
* Participating in another clinical trial.
* Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use.
* On Coumadin/ warfarin.
* Unable to participate for the required duration of the study.
Interventions
DRUG
PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
DRUG
PharmaNord Placebo
DRUG
PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
Conditions
Gulf War SyndromePersian Gulf SyndromeMitochondrial Disorder, Respiratory Chain
Locations
UC San Diego
La Jolla, California 92093
United States